Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Double-blind, Randomized, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury

NCT02669849 is registered in ClinicalTrials.gov with Vertex Pharmaceuticals Incorporated as lead sponsor.

NCT NCT02669849
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02669849 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Double-blind, Randomized, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury
Lead sponsor
Vertex Pharmaceuticals Incorporated
Phase
Phase 2/3
Overall status
Terminated
Start date
July 31, 2016
Completion date
November 30, 2018
Enrollment
70 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

cervical spinal cord injury